Showing results (11-20 of 49) with videos related to
Sort By:
Pageof 5
The Lancet. Oncology|January 15, 2013
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trialIstvan Lang, Thomas Brodowicz, Larisa Ryvo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE StudyEdith A Perez, Carlos Barrios, Wolfgang Eiermann, et al.Clinical Breast Cancer|December 31, 2005
Reducing the global breast cancer burden: the importance of patterns of care researchKathy S Albain, Jaime de la Garza Salazar, Tadeusz Pienkowski, et al.The New England Journal of Medicine|December 14, 2011
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerJosé Baselga, Javier Cortés, Sung-Bae Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2004
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19Leonard Reyno, Lesley Seymour, Dongsheng Tu, et al.Breast Cancer Research : BCR|February 11, 2017
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancerGiampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, et al.Journal of the National Cancer Institute|May 20, 2004
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerMark D Pegram, Tadeusz Pienkowski, Donald W Northfelt, et al.Cancer|July 19, 2019
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNEEdith A Perez, Carlos Barrios, Wolfgang Eiermann, et al.BMC Cancer|June 26, 2019
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancerEdith A Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, et al.BMC Cancer|June 1, 2019
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancerEdith A Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, et al.Pageof 5